Investors Newsletter

Number 7 April 1 2015

To our Partners, Friends and Shareholders: Happy Holiday

We have received additional comments to our trial submission from the FDA. We are currently addressing the comments raised by the FDA and preparing for re-submission soon. Our trial protocol is well refined and we are waiting to be approved in order to start the trial.

In parallel, we are preparing for the CE inspection. We have finalized all required testing and documentation for it and we anticipate the inspection to take place during second quarter; hopefully soon after to be approved for renewal of our CE mark.

We have edited the testimonial treatments that were presented in a physician conference in Argentina November 2014. You can view the doctors' satisfaction from the device on the testimonial section of our web site and on YouTube www.youtube.com/watch?v=vYnTVMXz53M and www.youtube.com/watch?v=lggAzOWNRZk

Conference presentation in Argentina

During March, we have conducted few presentation meetings with brokers and investors in the USA, in order to introduce our company, our product and our business strategy. We gave group presentations in Florida and New York. Interest was high and we are currently following up and keeping contact through our investor relation program headed by Redington Inc., in the USA (http://www.redingtoninc.com/)

Ron Weissberg presenting E-QURE to investors and brokers in NYC.

We filed our application for "Israel Health Basket" to NLHS (National List of Health Services)

www.health.gov.il
המינהל לטכנולוגיות רפואיות ותשתיות
Medical Technology and Infrastructure Administration
משרד הבריאות

Assessment Division in the Ministry of Health. This, in order to be eligible for national health insurance coverage approval in Israel. The approving committee is going to conduct its discussion during 2015 and we hope to be approve for the 2016 Israel health basket.

Itsik Ben Yesha, CTO is submitting E-QURE BST to the committee.

E-QURE Corp. 20 w 64 St. New York, NY 10023, USA.
www.e-qure.com.
info@e-qure.com

Investors Newsletter

Number 7 April 1 2015

E-QURE
ELECTRIC QUICK ULCER REMEDY

We are conducting initial discussions with potential distributors in Europe, South America and Israel. We hope to have at least one in place before 2015 yearend. As part of it we are preparing for additional Clinical Pilot Trials that will take place in those territories.

We are currently in the process of manufacturing pilot batch of the E-QUER BST devices, in Israel, using outsourced approved production facilities. This, in order to refine our production capabilities and be ready for commercial production of the BST device.

As we indicated in the past, we are going to file to the SEC a Sub-S document to release additional batch of our investors' shares for trading. Please continue to look us up under our symbol EQUR.

Our investor relation firm prepared an effective short "At a glance" document on our company to be presented to potential brokers and investors. In is attached for your review. Enjoy.


at a glance™

E-QURE

Published by Redington, Inc. for investment professionals. All rights reserved.

Recent Events: *E-QURE expects to initiate an FDA registration trial of its late-stage wound care device in Q3 2015 with top-line data due 4Q 2016; technology is first to mimic natural wound healing mechanisms at chronic wound sites; product economics not only extremely competitive, but also in line with existing U.S. reimbursement codes. Limited marketing underway in Europe under CE Mark--U.S. market launch anticipated for early 2017.*

Heading snapshot of our 'at a glance' document

All our previous newsletters and announcements can be found also on our web site www.e-qure.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. We are using forward-looking statements, when we discuss items in this document. These forward-looking statements and their implications are based on the current expectations of the management of E-QURE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QURE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, E-QURE undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QURE, reference is made to E-QURE's reports filed from time to time with the Securities and Exchange Commission.

E-QURE Corp. 20 w 64 St. New York, NY 10023, USA.
www.e-qure.com.
info@e-qure.com